PositiveID Corporation Receives an Additional Key Patent for Fieldable Biological Detection

Portable technology can be used to detect pathogens in both field and clinical environments for rapid diagnosis and treatment

DELRAY BEACH, FL - August 02, 2011 - PositiveID Corporation ("PositiveID" or "Company") (Nasdaq:PSID - News), a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, announced today that it has been awarded an additional important international patent "Apparatus and Method of Extracting and Optically Analyzing an Analyte from a Fluid-based Sample," (WO2008/005166) by the World Intellectual Property Organization. The technology represented by this new patent, awarded to the Company's MicroFluidic Systems ("MFS") subsidiary, works in conjunction with the patented technology which the Company announced in mid-July. The technologies provide key steps in accurate biological sample preparation and detection with limited resources, and in the field or clinical environment.

The handheld instrument is small enough, about the size of a syringe, that it could be carried easily by a medical provider and used with a minimal amount of training and time. This technology can allow rapid detection within minutes of a sampling allowing appropriate treatment for infected individuals immediately. The system works entirely on batteries.

Dr. M. Allen Northrup, CEO of MFS, said, "The two new patents announced over the past couple of weeks are noteworthy for their ability to run biological sample analysis in a small, portable and cost-efficient format and provide rapid, accurate detection. We believe this technology has significant value for multiple applications of critical importance to prevent disease outbreaks and save lives."

The unique component of the technology is a very low power optical analysis system directly coupled to the collection system to perform optical analysis on multiple collected analytes. The purification device includes a plurality of capture surfaces coated with specific capture chemistries. The specific capture can be for a nucleic acid, protein or other target analyte, and multiple options for optical detection exist.

PositiveID acquired MFS in May 2011. MFS specializes in the production of automated instruments for a wide range of applications in the detection and processing of biological samples. MFS' strong portfolio of intellectual property related to sample preparation and rapid medical testing applications are complementary to PositiveID's portfolio of virus detection and diabetes management products.

About PositiveID Corporation
PositiveID Corporation develops unique medical devices and biological detection systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MicroFluidic Systems, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.

Company Profile - PositiveID Corporation

PositiveID Corporation (NASDAQ: PSID) develops unique medical devices and biological detection systems focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MicroFluidic Systems or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID Corporation was formed on November 10, 2009 through the merger of VeriChip Corporation and Steel Vault Corporation.

In May 2011, PositiveID acquired California-based Microfluidic Systems, founded in 2001, which specializes in the development and production of automated instruments for detecting and processing of biological samples. MFS' core technology is used for airborne pathogen detection, rapid clinical diagnostics and sample preparation applications.

MFS' microfluidic technology alleviates all existing problems by replacing robotics with integrated microfluidics, reducing cost and increasing reliability. Our microfluidic technology also automates and increases the effectiveness of key sample processing steps used today on the laboratory bench-top, into a closed automated system. The embedded devices perform cell lysis (including difficult spores) in less than 1 minute at low power, nucleic acid purification along with inhibitor removal and pre-concentration of the nucleic acids up to factors of 1000X within minutes. These processes all occur autonomously within a fully contained disposable microfluidic cartridge.

PositiveID operates in two main divisions: HealthID and SecurityID. The HealthID segment develops unique medical devices, focused primarily on diabetes management, and rapid medical testing applications. Its SecurityID segment develops airborne bio-threat detection systems.

An integral part of the history of PositiveID is its radio-frequency identification (RFID) implantable microchip for patient identification, the VeriChip. The company's RFID microchip traces back to the events of September 11, 2001, when New York firemen wrote their badge ID numbers on their chests in case they were found injured or unconscious. It was evident there was a serious need for personal information in emergency situations and the product, modeled after a similar microchip used in pets, evolved from there. The company received FDA clearance for the microchip in October 2004.

Consider Investing in PositiveID Corporation

Shares trade in the range of 0.42 - 0.46 dollars.

It has a market capitalization of 16.02M dollars and has 37.27M outstanding shares.

The company has a beta of 1.19, indicating, the stock to be more volatile than the market.

As per the most recent quarterly report, the net income per share (EPS) is -0.67.

It operates in Technology sector and belongs to Scientific and Technical Instr. industry.

The organization is engaged in developing radio frequency identification systems used for the healthcare market.

The company has a 52 week high of $ 1.58 and a 52 week low of $ 0.40.

Average volumes of shares traded daily are 504,846.00.

Volume traded in the last session was at 142,355.00, 0.28 times the average volume.

FORWARD LOOKING STATEMENTS These news releases include forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements that reflect PositiveID Corporation's current expectations about its future results, performance, prospects and opportunities. PositiveID Corporation has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "hope," or similar expressions. These forward-looking statements are based on information currently available to PositiveID Corporation and are subject to a number of risks, uncertainties and other factors that could cause PositiveID Corporation's actual results, performance, prospects or opportunities in the remainder of 2011 and beyond to differ materially from those expressed in, or implied by, these forward-looking statements. These risks are referenced in PositiveID Corporation's current 10K or as may be described from time to time in PositiveID Corporation's subsequent SEC filings; and such factors as incorporated by reference.

DISCLAIMER: This is a paid advertisement provided to our subscribers. Although we have sent you this email, Financial Market Advisor does not endorse this product or company nor is it responsible for the content of this ad. Furthermore, we make no guarantee or warranty about what is advertised above, and have not independently reviewed the information provided within this advertisement.

In accordance with Section 17(b) of the Securities Act of 1933, you are hereby advised that Financial Market Advisor is receiving a fee of $3,000 in cash, from Hanover Financial Services as compensation for the distribution of this advertisement. Financial Market Advisor has not determined if the statements and opinions of the advertiser are accurate, correct or truthful. The purpose of this advertisement, like any advertising, is to provide publicity for the advertising company, its products or services. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment.

Advertisements received by you are not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the States or other jurisdictions in which the security is eligible for sale. Advertisements distributed through disseminated emails are not disclosure documents. If you are considering purchasing any securities of an advertised company, you should call your State Securities Administrator to determine if the security may be sold in your State. Many companies have information filed with State securities regulators who may be able to supply you with additional information. You also should read and review, if and to the extent available, any information concerning an advertised company available at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at http://www.sec.gov and the National Association of Securities Dealers (the "NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud at http://www.sec.gov/consumer/cyberfr.htm, as well as related information published by the NASD on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence.

Advertiser:
Hanover Financial Services
Ph: (303) 494-3617
info@hanoverfinancialservices.com